Establishment of a 5-fluorouracil-resistant triple-negative breast cancer cell line

International Journal of Oncology

Volumn 43, Issue 6, 2013, Pages 1985-1991

  Takahashi, Katsuyuki ^a,b   Tanaka, Masako ^a   Inagaki, Azusa ^a   Wanibuchi, Hideki ^a   Izumi, Yasukatsu ^a   Miura, Katsuyuki ^a   Nagayama, Katsuya ^b   Shiota, Masayuki ^a   Iwao, Hiroshi ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA CITY UNIVERSITY HOSPITAL   (Japan)

Author keywords

5 fluorouracil; Drug resistant cell; Triple negative breast cancer

Indexed keywords

CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; GEMCITABINE; NAVELBINE; PACLITAXEL; PROGESTERONE RECEPTOR;

ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL CYCLE; CELL DEATH; CONTROLLED STUDY; DNA RECOMBINATION; DRUG INDICATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEOMICS; TRIPLE NEGATIVE BREAST CANCER;

ANTINEOPLASTIC AGENTS; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; PACLITAXEL; PROTEOME; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TRIPLE NEGATIVE BREAST NEOPLASMS; VINBLASTINE;

EID: 84891938948     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2135     Document Type: Article

References (34)

1. Foulkes WD, Smith IE and Reis-Filho JS: Triple-negative breast cancer. N Engl J Med 363: 1938-1948, 2010.
2. Liedtke C, Mazouni C, Hess KR, et al: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26: 1275-1281, 2008.
3. Thike AA, Cheok PY, Jara-Lazaro AR, et al: Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. Mod Pathol 23: 123-133, 2010.
4. Dent R, Trudeau M, Pritchard KI, et al: Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13: 4429-4434, 2007.
5. Isakoff SJ: Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J 16: 53-61, 2010.
6. Marquette C and Nabell L: Chemotherapy-resistant metastatic breast cancer. Curr Treat Options Oncol 13: 263-275, 2012.
7. Chen ZS and Tiwari AK: Multidrug resistance proteins (MRPs/ ABCCs) in cancer chemotherapy and genetic diseases. FEBS J 278: 3226-3245, 2011.
8. Baguley BC: Multiple drug resistance mechanisms in cancer. Mol Biotechnol 46: 308-316, 2010.
9. Abraham J, Edgerly M, Wilson R, et al: A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine. Clin Cancer Res 15: 3574-3582, 2009.
10. Ruff P, Vorobiof DA, Jordaan JP, et al: A randomized, placebocontrolled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen. Cancer Chemother Pharmacol 64: 763-768, 2009.
11. Zheng G, Peng F, Ding R, et al: Identification of proteins responsible for the multiple drug resistance in 5-fluorouracilinduced breast cancer cell using proteomics analysis. J Cancer Res Clin Oncol 136: 1477-1488, 2010.
12. Nakamura A, Nakajima G, Okuyama R, et al: Enhancement of 5-fluorouracil-induced cytotoxicity by leucovorin in 5-fluorouracil-resistant gastric cancer cells with upregulated expression of thymidylate synthase. Gastric Cancer: Mar 15, 2013 (Epub ahead of print).
13. Kodera Y, Ito S, Fujiwara M, et al: Gene expression of 5-fluorouracil metabolic enzymes in primary gastric cancer: correlation with drug sensitivity against 5-fluorouracil. Cancer Lett 252: 307-313, 2007.
14. Ichikawa W, Takahashi T, Suto K, et al: Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer. Br J Cancer 91: 1245-1250, 2004.
15. Longley DB, Harkin DP and Johnston PG: 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3: 330-338, 2003.
16. Zhang X, Yashiro M, Qiu H, et al: Establishment and characterization of multidrug-resistant gastric cancer cell lines. Anticancer Res 30: 915-921, 2010.
17. Uchibori K, Kasamatsu A, Sunaga M, et al: Establishment and characterization of two 5-fluorouracil-resistant hepatocellular carcinoma cell lines. Int J Oncol 40: 1005-1010, 2012.
18. Yanagihara K, Takigahira M, Tanaka H, et al: Establishment and molecular profiling of a novel human pancreatic cancer panel for 5-FU. Cancer Sci 99: 1859-1864, 2008.
19. Kakehashi A, Ishii N, Shibata T, et al: Mitochondrial prohibitins and septin 9 are implicated in the onset of rat hepatocarcinogenesis. Toxicol Sci 119: 61-72, 2011.
20. Park JS, Young Yoon S, Kim JM, et al: Identification of novel genes associated with the response to 5-FU treatment in gastric cancer cell lines using a cDNA microarray. Cancer Lett 214: 19-33, 2004.
21. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 88: 323-331, 1997.
22. Shieh SY, Ikeda M, Taya Y, et al: DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91: 325-334, 1997.
23. Tibbetts RS, Brumbaugh KM, Williams JM, et al: A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev 13: 152-157, 1999.
24. Shin JY, Kim JO, Lee SK, et al: LY294002 may overcome 5-FU resistance via down-regulation of activated p-AKT in Epstein-Barr virus-positive gastric cancer cells. BMC Cancer 10: 425, 2010.
25. Yanamoto S, Iwamoto T, Kawasaki G, et al: Silencing of the p53R2 gene by RNA interference inhibits growth and enhances 5-fluorouracil sensitivity of oral cancer cells. Cancer Lett 223: 67-76, 2005.
26. Chu E, Drake JC, Koeller DM, et al: Induction of thymidylate synthase associated with multidrug resistance in human breast and colon cancer cell lines. Mol Pharmacol 39: 136-143, 1991.
27. Peters GJ, Backus HH, Freemantle S, et al: Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta 1587: 194-205, 2002.
28. Chen J, Shen BY, Deng XX, et al: SKP1-CULLIN1-F-box (SCF)-mediated DRG2 degradation facilitated chemotherapeutic drugs induced apoptosis in hepatocellular carcinoma cells. Biochem Biophys Res Commun 420: 651-655, 2012.
29. Nakayama KI and Nakayama K: Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer 6: 369-381, 2006.
30. Chan CH, Li CF, Yang WL, et al: The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis. Cell 149: 1098-1111, 2012.
31. Zhu D, Cardenas ME and Heitman J: Calcineurin mutants render T lymphocytes resistant to cyclosporin A. Mol Pharmacol 50: 506-511, 1996.
32. Colgan J, Asmal M, Yu B, et al: Cyclophilin A-deficient mice are resistant to immunosuppression by cyclosporine. J Immunol 174: 6030-6038, 2005.
33. Wong CS, Wong VW, Chan CM, et al: Identification of 5-fluorouracil response proteins in colorectal carcinoma cell line SW480 by two-dimensional electrophoresis and MALDI-TOF mass spectrometry. Oncol Rep 20: 89-98, 2008.
34. Kuramitsu Y, Taba K, Ryozawa S, et al: Identification of up- and down-regulated proteins in gemcitabine-resistant pancreatic cancer cells using two-dimensional gel electrophoresis and mass spectrometry. Anticancer Res 30: 3367-3372, 2010.